ANTICANCER INC. PLANNING CLINICAL TRIALS AT THREE SOVIET HOSPITALS
Executive Summary
ANTICANCER INC. PLANNING CLINICAL TRIALS AT THREE SOVIET HOSPITALS under recent agreements with the institutions. The San Diego contract testing firm plans to enter into additional individual contracts with U.S. drug companies to carry out clinical testing of anticancer drugs in the Soviet Union. The firm has not yet reached any agreements with drug firms, but AntiCancer President Robert Hoffman says trials "could begin in the next few months." The three hospitals, all located in Moscow, are the All Union Cancer Research Center, the All Union Scientific Center for Hematology and the Herzen Moscow Cancer Research Institute. Hoffman said the Soviet hospitals are "centralized institutions with large patient populations" that offer the opportunity to conduct a clinical trial with a large population "under standard uniform conditions." Under the agreement with the hospitals, AntiCancer will have access to patient records. AntiCancer Inc. was founded three years ago by Hoffman and Hara Stuthas, both from the University of California at San Diego, where Hoffman is a professor. Hoffman said AntiCancer has conducted preclinical trials for five major pharmaceutical companies. The privately-held company will first conduct preclinical trials of a drug in the U.S. before offering to do clinicals in the Soviet Union. Hoffman began collaborating with scientists in the Soviet Union 15 years ago, as a participant in the National Academy of Sciences scientist exchange program. AntiCancer Inc. has obtained four Small Business Innovation Research (SBIR) grants from the National Cancer Institute in the last two years. The grants were for development of technology for drug development and evaluation and for the development of DNA probes for the diagnosis of colon cancer and pre-malignancy.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth